New hope for kids with rare sleep epilepsy?
NCT ID NCT04625101
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug called NBI-827104 in 24 children with a rare epilepsy that causes constant brain spikes during sleep. The drug is a calcium channel blocker given daily for 13 weeks. The main goal was to see if it reduces abnormal brain activity measured by EEG.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-827104 (a calcium channel blocker)
What this could lead to
If it works, this could point toward a new treatment to reduce seizure-like brain activity during sleep in children with this rare epilepsy.
What could go wrong
This is a small, early-phase trial with only 24 participants. The drug may not improve symptoms or could cause side effects. Results may not apply to all children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Orange, California, 92868, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Neurocrine Clinical Site
Miami, Florida, 33155, United States
-
Neurocrine Clinical Site
Rochester, Minnesota, 55905, United States
-
Neurocrine Clinical Site
Durham, North Carolina, 27710, United States
-
Neurocrine Clinical Site
Cleveland, Ohio, 44195, United States
-
Neurocrine Clinical Site
Philadelphia, Pennsylvania, 19104, United States
-
Neurocrine Clinical Site
Calgary, Alberta, T3B 6A8, Canada
-
Neurocrine Clinical Site
Dianalund, 4293, Denmark
-
Neurocrine Clinical Site
Barcelona, 08950, Spain
-
Neurocrine Clinical Site
Madrid, 28034, Spain
-
Neurocrine Clinical Site
Basel, 4031, Switzerland
-
Neurocrine Clinical Site
Zurich, 8032, Switzerland
-
Neurocrine Clinical Site
London, WC1N 3JH, United Kingdom